相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2010
已完成
4
80.0%
招募中
1
20.0%
暂无批准数据
- Oral RT-114 delivered via RaniPill Capsule achieved systemic exposure greater than 150% relative to a matched 12 mg subcutaneous dose of PG-102 in a 30-person Phase 1a study. - Elimination half-life was nearly identical between oral (5.6 days) and subcutaneous (5.3 days) arms, suggesting intact peptide delivery into systemic circulation. - No adverse events were attributed to the RaniPill Capsule device; treatment-related events were mild, transient, and consistent with the GLP-1/GLP-2 agonist class. - The Phase 1a study is being expanded with a 15-person cohort to further characterize dose-concentration relationships before a Phase 1b obesity study expected to begin in 2026.
- Rani Therapeutics appointed Dr. Sara Kenkare-Mitra as Strategic Advisor, bringing nearly three decades of biologics development experience and a track record of global regulatory approvals across multiple therapeutic areas. - The company also named Jesper Høiland as Head of Strategy, leveraging his 30+ years of pharmaceutical leadership experience and expertise in obesity and metabolic diseases. - Both appointments aim to advance the RaniPill® platform strategy and prioritize clinical programs with the greatest potential for meaningful impact, particularly following encouraging preclinical data with oral semaglutide. - The strategic hires position Rani to capitalize on the potential of oral biologic delivery across multiple therapeutic areas and support future partnering opportunities.
- Rani Therapeutics has initiated a Phase 1 clinical trial evaluating RT-114, an oral RaniPill capsule containing the GLP-1/GLP-2 dual agonist PG-102 for obesity treatment. - Preclinical testing demonstrated that RT-114 delivered via RaniPill achieved bioavailability, pharmacokinetics, and weight loss comparable to subcutaneous injection in animal models. - The collaboration with ProGen aims to develop an oral alternative to injectable obesity medications, potentially expanding patient access and improving treatment experience. - PG-102 has shown glucose-lowering effects and meaningful early weight-loss signals in preclinical and clinical data presented at the 2025 EASD meeting.
- Rani Therapeutics will present preclinical data showing oral semaglutide (RT-116) delivered via RaniPill capsule is bioequivalent to subcutaneous injections in dogs. - The study demonstrates that oral delivery through the RaniPill platform elicits similar weight loss effects compared to traditional injection methods. - The presentation will take place at ObesityWeek 2025 on November 6, 2025, showcasing the company's novel oral delivery technology for biologics. - This development represents a potential breakthrough in replacing subcutaneous injections with oral dosing for diabetes and obesity treatments.
- Rani Therapeutics has entered a research agreement with Chugai Pharmaceutical to evaluate the application of its RaniPill® oral delivery technology for Chugai's antibodies against undisclosed targets. - Initial analysis confirms RaniPill® delivery demonstrated comparable bioavailability to subcutaneous injection for both molecules studied, potentially transforming how biologics are administered. - The collaboration leverages Rani's expertise in oral biologics delivery with Chugai's antibody engineering capabilities, aiming to address the challenge of oral administration for complex biological drugs.
- Rani Therapeutics demonstrated that RT-114, an oral GLP-1/GLP-2 dual agonist delivered via RaniPill® capsule, achieved 111% bioavailability compared to subcutaneous injection in preclinical studies, with comparable weight loss outcomes. - The company's RaniPill® platform has successfully delivered four incretin-based molecules orally, including semaglutide, positioning Rani to potentially transform obesity treatment by eliminating the need for injections. - A Phase 1 clinical trial for RT-114 is expected to begin in mid-2025, with the company aiming to develop the first-in-class oral GLP-1/GLP-2 dual agonist for obesity treatment.
